IMUNON Inc. (IMNN), a clinical-stage biotechnology firm, recently announced a favorable recommendation from an Independent Data Monitoring Committee (IDMC) regarding the Phase 2 minimal residual disease (MRD) trial for IMNN-001 in ovarian cancer.
IMNN-001 is an IL-12 DNA plasmid vector encapsulated in a nanoparticle delivery system that transfects cells and secretes IL-12 proteins. This brings about a concerted anti-cancer effect through the proliferation of T-lymphocytes and natural killer cells.
The ongoing, multi-site, randomized Phase 2 MRD study is being conducted in collaboration with the Break Through Cancer organization at the University of Texas MD Anderson Cancer Center. The controlled translational trial is dosing patients who have completed a standard-of-care chemotherapy regimen with bevacizumab, with or without IMNN-001, in women with newly diagnosed or advanced ovarian cancer.
Preliminary results disclosed by the company in July 2026 indicated a lower rate of MRD positivity among treated patients, amounting to 44%, compared to 67% in the placebo group.
Those administered IMNN-001 also exhibited a higher clearance of circulating DNA (ctDNA) at 87.5%, while those on the placebo showed 62.5% clearance.
The IDMC reported observing an absence of cytokine release syndromes, systemic toxicities, or severe immune-related adverse effects among treated patients. Accordingly, the panel of independent medical experts in gynecological cancers ruled that the findings justified the advancement of the drug in the Phase 3 OVATION 3 study.
Also Read
- Escalating Aerial Warfare Claims Lives as Trump Urges Zelenskyy-Putin Settlement
- Jumblatt’s Shifting Positions on the Washington Framework: A Window into Lebanon’s Power Dynamics
- Investing in AGNC: Calculating Shares Needed to Match a Typical Mortgage Payment
- Backlash over data centers tests Europe’s AI ambitions
